Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:42:11.488Z.
Calculation as of: 2026-10-06T19:42:11.488Z.
Quote observation: 2026-10-06T19:40:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.59B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.62B
EV/FCF Ratio
N/A
TTM Avg
14.99x
3Y Avg
23.02x
5Y Avg
23.02x
Market Cap
$1.63B
EV/FCF Ratio
507.92x
TTM Avg
489.34x
3Y Avg
489.34x
5Y Avg
489.34x
Market Cap
$1.55B
EV/FCF Ratio
N/A
TTM Avg
25.30x
3Y Avg
25.30x
5Y Avg
25.30x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.59B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 10.63x | 16.48x | 13.59x | 55.24x |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.60B | N/A | N/A | N/A | N/A |
| uniQure N.V. (QURE)vs › | $1.61B | N/A | 2.09x | 2.12x | 2.12x |
| Septerna Inc (SEPN)vs › | $1.61B | 14.75x | 11.48x | 11.48x | 11.48x |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | N/A | 14.99x | 23.02x | 23.02x |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.63B | 507.92x | 489.34x | 489.34x | 489.34x |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.55B | N/A | 25.30x | 25.30x | 25.30x |
| Innoviva, Inc. (INVA)vs › | $1.54B | 6.56x | 8.16x | 9.35x | 8.17x |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.53B | N/A | 61.87x | 61.87x | 61.87x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
